Management of severe infusion reactions after cetuximab.
Cerman
Jaroslav
J
Department of Surgery, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic.
Melichar
Bohuslav
B
Cermanova
Melanie
M
Solichova
Dagmar
D
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D004342:Drug Hypersensitivity / Q000188:drug therapy / Q000209:etiology*; D066246:ErbB Receptors / Q000276:immunology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab